Navigation Links
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
Date:4/7/2008

VIENNA, Austria, April 7 /PRNewswire/ -- A biosimilar product for treating the negative effects that cancer chemotherapy can have on the white blood cells of patients is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. This is the result of a clinical phase I trial conducted jointly by the Austrian company Kwizda Pharma GmbH and the Indian manufacturer INTAS Biopharmaceuticals Ltd. (IBPL). Upon completion of an upcoming clinical phase III trial, both companies will lodge an application to get the product approved for the European market. The market launch is planned for early 2010.

Neutropenia - a condition whereby the concentration of neutrophils (a type of white blood cell) in the blood is too low - is a serious side effect of cancer chemotherapy and can prevent the treatment from being successful. Granulocyte colony stimulating factor (G-CSF) is a human protein that can reverse neutropenia by initiating the production of neutrophils. Recombinant forms of the protein have already been approved for the European market. However, due to the high costs that are involved, the relevant authority (EMEA) is encouraging applications for biosimilar products.

Similar & Identical

Working in partnership with IBPL, the first and only biopharmaceutical company in India to comply with EU Good Manufacturing Practice (GMP), Kwizda Pharma has now completed a clinical phase I trial as part of the European application process for a biosimilar form of recombinant G-CSF known as Neukine. Neukine exhibits identical efficacy to the EU-approved reference product. Dr. Helmut Brunar, VP of Research & Business Development at Kwizda Pharma sums up the results of the trial: "Not only was Neukine cleared from the patients' blood plasma just as quickly as the reference, but the number of neutrophils also increased with identical kinetics after treatment. We are very pleased with these results." The study was a
'/>"/>

SOURCE Kwizda Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. Increasing Dairy Milk Production with Electrolyzed Drinking Water
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
7. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
11. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... RUTHERFORD, N.J., May 1, 2015 Cambrex Corporation (NYSE: ... March 31, 2015. Highlights , ... and increased 27% excluding foreign currency impact, driven by Innovator ... million from $8.4 million in the first quarter of 2014. ... versus $0.04 in the first quarter last year and Adjusted ...
(Date:4/30/2015)... Calif., April 30, 2015 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Fourth quarter and fiscal 2015 overview: ... the fourth quarter, up 33% over last year,s comparable ... year-over-year. , Diluted EPS of $0.50 for the ...
(Date:4/30/2015)... April 30, 2015  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2015 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, May 7, 2015 ... business developments. Interested parties may access the ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... Mich. , June 14 Stryker Corporation ... of its manufacturing facilities have earned Leadership in Energy ... Building Council (USGBC).  LEED is an internationally recognized green ... a framework for identifying and implementing practical and measurable ...
... , June 14 Codexis, Inc. (Nasdaq: CDXS) ... Officer, received the Ernst & Young Entrepreneur Of The Year ® ... , , , ... Young LLP, the award recognizes outstanding entrepreneurs who are building and leading ...
Cached Medicine Technology:Stryker Facilities Earn LEED® Certifications 2Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California 2Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California 3
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 NuevaCare ... MnemeTherapy® at two upcoming area seminars. The first event ... PSA Annual Regional Stroke Conference to be held at ... offered on Wednesday, May 13 during the Dementia Conference ... , “These seminars offer an excellent opportunity to ...
(Date:5/3/2015)... 2015 HealthPostures, a pioneering ergonomics ... its appearance at the , May 5 - 7, ... will exhibit at the conference include its bestselling TaskMate ... solutions is the 6100 TaskMate Executive. Features of the ... adjustable keyboard tray, extended platform work surface and supply ...
(Date:5/2/2015)... BC (PRWEB) May 02, 2015 Vancouver fencing ... will now provide valuable advice to prospective clients related to ... are looking to install railings around their decks and patios. ... several questions that pop up once the person rolls up ... phases of installing a railing in finding a gate that ...
(Date:5/2/2015)... It’s a pattern that won’t relent anytime ... on this planet, cyber scammers will immediately be thinking ... their own personal gain. And on April 30, ... issued an alert titled “Nepal Earthquake Disaster Email Scams,” ... earthquake in Nepal. The scam emails may contain links ...
(Date:5/2/2015)... On Tuesday April 7th, the patient care ... celebrate improvements in patient care. In 2014 the hospital, ... zero acquired ventilator associated infections, zero central line associated ... also recently named a Top Performer by the Joint ... the teamwork of staff from all departments involved in ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... are planning to study the relationship between global warming ... will be funded by the U.S. Centers for Disease ... individuals have died due to the heat wave that ... track the rising temperature to these illness and deaths ...
... have seen evident improvement in the death rates of Aborigines ... benefits of improved healthcare that has brought down death rates ... of funds into healthcare will see far more results in ... and quality of life., ,The study's leader, David ...
... of graphic pictures on cigarette packets, Benson and Hedges, a ... reinventing the packaging of cigarettes in tins which carry health ... removed. , ,Action on Smoking and Health (ASH) ... for inventing ways to reduce the impact of health warnings ...
... Reports have indicated that doctors in the US U.S. ... the condition, leaving some patients to suffer for years.// ... diseases in the world, and according to the World ... million in the year 2004. A tuberculosis bacterium has ...
... FDA-approved tool to treat drug-resistant HIV thanks to a ... ,"There are many treatments for AIDS on the market, ... Arun Ghosh (pronounced A-rune GO-sh), a professor with a ... chemistry and molecular pharmacology. "This is the first treatment ...
... women with endometrial cancer should be screened for inherited ... several other cancers.// ,The study showed that ... diagnosed endometrial cancer patients have mutations for Lynch syndrome, ... cancer, or HNPCC. ,People with Lynch syndrome ...
Cached Medicine News:Health News:Doctors In US Lack Skills For The Diagnosis Of TB 2Health News:Research Leads to First Treatment for Drug-Resistant HIV 2Health News:Research Leads to First Treatment for Drug-Resistant HIV 3Health News:Research Leads to First Treatment for Drug-Resistant HIV 4Health News:Uterine Cancer May be Clue to Inherited Syndrome 2Health News:Uterine Cancer May be Clue to Inherited Syndrome 3
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
... chemistry integrated systems combine the ease of ... power of the Multiply and Quicklyte integrated ... module to meet the challenges of your ... menus, the systems can meet over 97% ...
The Embla 96/384 well washer is a top-loading, robotic-compatible plate washer for 96- and 384-well microplate washing. It is ideal for ELISAs and most cell applications....
Auto Plate Washer: 96-well washing. The ELx405 Auto Washer is the most precise and reliable washer available. Many unique features lower background absorbance values and increase the signal-to-noise ...
Medicine Products: